SMS Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 29, 2025
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SMS Pharmaceuticals held its 37th AGM on September 29, 2025 via video conferencing, where all 7 resolutions were passed with overwhelming shareholder approval (over 99.98% in favor on every item). Key items approved include adoption of FY25 financial statements, declaration of dividend on equity shares for FY 2024-25, re-appointment of Mr. Trilok Potluri (retiring by rotation), approval of material related party transactions with VKT Pharma Private Limited, remuneration for Cost Auditors for FY 2025-26, appointment of Secretarial Auditors, and re-appointment of Mr. Vamsi Krishna Potluri as Executive Director with fixed remuneration (special resolution). Out of 35,604 total shareholders, only 218 participated in voting; the promoter group (holding ~66.3% stake) abstained on resolutions where they had an interest, namely the re-appointment of directors and the related party transaction with VKT Pharma. The Scrutinizer (C. Sudhir Babu, Practicing Company Secretary) confirmed that the e-voting process was fair and transparent, with results declared on the same day.
Routine procedural filing confirming that shareholders have approved all standard AGM agenda items, including a dividend for FY25 and a related party transaction with VKT Pharma. No contentious resolutions or close votes; the related party transaction and executive director re-appointment passed despite promoter abstention, supported by public institutional and retail shareholders. Limited share price impact expected as outcomes are broadly as anticipated.